Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical (LFCR) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to 14.62%.

  • Lifecore Biomedical's EBITDA Margin rose 894.00% to 14.62% in Q2 2025 from the same period last year, while for May 2025 it was -13.38%, marking a year-over-year decrease of 2995.00%. This contributed to the annual value of -13.38% for FY2025, which is 649.00% down from last year.
  • Per Lifecore Biomedical's latest filing, its EBITDA Margin stood at 14.62% for Q2 2025, which was up 156.91% from -25.68% recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's EBITDA Margin registered a high of 47.16% during Q4 2023, and its lowest value of -137.58% during Q1 2023.
  • For the 3-year period, Lifecore Biomedical's EBITDA Margin averaged around -17.01%, with its median value being -13.66% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by 11,022bps in 2023, then soared by 18,136bps in 2024.
  • Lifecore Biomedical's EBITDA Margin (Quarterly) stood at 14.41% in 2021, then tumbled by 7,168bps to -57.26% in 2022, then surged by 10,442bps to 47.16% in 2023, then plummeted by 5,317bps to -6.02% in 2024, then soared by 894bps to 14.62% in 2025.
  • Its EBITDA Margin was 14.62% in Q2 2025, compared to -25.68% in Q1 2025 and -6.02% in Q4 2024.